In the present
paper, the authors showed the results of a meta-analysis study aimed at evaluating the pathogenic bases and the clinical manifestations of the overlapping syndromes related to Lamin A/C gene and identifying a possible relationship between the selleck Rucaparib complex phenotypes producing the overlapping syndromes and the mutations of LMNA gene. Materials and methods We searched, by indicating in PubMed as keywords LMNA and Lamin A/C, for all papers reporting the overlapping syndromes related to LMNA gene mutations. We also looked at the UMD-LMNA mutations databases (14) [http://www.umd.be/LMNA/ (Universal Mutation Database The UMD-LMNA mutations Inhibitors,research,lifescience,medical database)] and Leiden muscular Dystrophy database (15) [http://www.dmd.nl/ Inhibitors,research,lifescience,medical (Leiden Muscular Dystrophy pages©)] in order to identify all the dominant LMNA gene mutations associated to overlapping syndromes and the papers cited in the references. We prepared a database containing the mutations identified and the complex phenotypes associated to the mutations, specifying the tissues and organs compromised; we also indicated any alterations
of metabolisms or signs of premature ageing. Then, we considered Inhibitors,research,lifescience,medical the type of mutation, its position on the gene and on the protein, the effect on the aminoacidic sequence and the possible pathogenic role (haploinsufficiency, poison peptide effect) exerted by the mutations. We also calculated the frequency of the mutations per exon, associated to the overlapping syndromes. Finally, COILS software was applied to predict the coiled-coil forming and the heptad position for each aminoacidic substitution evaluated. Coils software gives a score from 0 to 1 (0: no possibility of coiled coil; 1: highest probability of coiled Inhibitors,research,lifescience,medical coil), according to the probability for the aminoacid to belong to the coiled-coil region (67).
Results Table 1 shows the complex phenotypes related to dominant LMNA gene mutations and the characteristics of the genetic alterations. Of the identified syndromes, 69 cases are associated to 46 dominant mutations, 41 of them proved to be unique Inhibitors,research,lifescience,medical missense mutations located in 41 different positions; 31 of the 41 missense mutations involve a polar aminoacid residue, which is mutated in an apolar aminoacid in about 50% of cases; the remaining 10 missense mutations involve an apolar residue and determine in half of the cases a substitution with an aminoacid Anacetrapib with the same polarity. Among the missense mutations, we decided to include c. 1698+13 C > T, p. Arg566 +5Cys selleck kinase inhibitor observed in exon10; we considered the mutation position as a terminal part of the gene region coding for C lamin. A higher frequency of mutations causing overlapping syndromes per exon was observed in exons 1-2, 8 and 9 (Table 2). About half of the missense mutations are located in coiled coils regions (predicted by COILS with a probability higher than 0.